New Insights on the Pharmacokinetics of Ulifloxacin After Administration of Prulifloxacin in Patients with Mild, Moderate and Severe Renal Impairment

BACKGROUND: The antibacterial agent prulifloxacin, a prodrug of ulifloxacin, is indicated in the treatment of acute lower urinary tract infections, acute exacerbation of chronic bronchitis and acute bacterial rhinosinusitis. OBJECTIVE: We aimed to provide new insights on the pharmacokinetics (PK) of...

Descripción completa

Detalles Bibliográficos
Autores principales: Tellone, Valeria, Coppola, Paola, Ammendola, Marco, Di Loreto, Giorgio, Picollo, Rossella, Del Vecchio, Alessandra, Comandini, Alessandro, Garofolo, Fabio, Tongiani, Serena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6131124/
https://www.ncbi.nlm.nih.gov/pubmed/30151791
http://dx.doi.org/10.1007/s40268-018-0245-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6131124/
https://www.ncbi.nlm.nih.gov/pubmed/30151791
http://dx.doi.org/10.1007/s40268-018-0245-9

Ejemplares similares